Home › NDC Lookup › RxCUI directory › RxCUI 198181

Pyrazinamide 500 MG Oral Tablet — RxCUI 198181

RxNorm drug concept · Semantic clinical drug
RxCUI 198181 Semantic clinical drug · SCD ● Current RxNorm concept 5 FDA products 18 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI198181
Official namePyrazinamide 500 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asPZA 500 MG Oral Tablet
FDA products mapped5
Package NDCs mapped18
Reported Medicaid activity (SDUD)1,725 prescriptions · 10 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Pyrazinamide: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • TB is a tough infection, and using just one antibiotic gives the bacteria a chance to become resistant and stop responding to treatment. Pyrazinamide works best — and helps protect...
  • Why do I have to take so many pills at once — can't I just take pyrazinamide by itself?
  • The standard plan recommended by the CDC is a 6-month course for drug-susceptible TB. Pyrazinamide is typically used during the first 2 months of that period, alongside other medic...
  • How long will I need to take this medication?
📖 Read our full Pyrazinamide guide →

🕸️ Concept Web — How Pyrazinamide 500 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Pyrazinamide 500 MG Oral Tablet RxCUI 198181

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Pyrazinamide 8987
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Pyrazinamide Oral Tablet 373701
    • Pyrazinamide Oral Product 1163600
    • Pyrazinamide Pill 1163601
    • Oral Tablet 317541
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Pyrazinamide 500 MG 360768

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Pyrazinamide 500 MG SCDC · 360768
  • Pyrazinamide Oral Tablet SCDF · 373701
  • Pyrazinamide Oral Product SCDG · 1163600
  • Pyrazinamide Pill SCDG · 1163601

📦 FDA Products & Package NDCs

5 products · 18 package NDCs
18 package NDCs map to RxCUI 198181 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00054-0812-21 60 TABLET in 1 CONTAINER (0054-0812-21) pyrazinamide Hikma Pharmaceuticals USA Inc 2024-08-30
00054-0812-22 90 TABLET in 1 CONTAINER (0054-0812-22) pyrazinamide Hikma Pharmaceuticals USA Inc 2024-08-30
00054-0812-25 100 TABLET in 1 CONTAINER (0054-0812-25) pyrazinamide Hikma Pharmaceuticals USA Inc 2024-08-30
00054-0812-29 500 TABLET in 1 CONTAINER (0054-0812-29) pyrazinamide Hikma Pharmaceuticals USA Inc 2024-08-30
10135-0735-01 100 TABLET in 1 BOTTLE (10135-735-01) PYRAZINAMIDE MARLEX PHARMACEUTICALS, INC 2022-03-01
10135-0735-60 60 TABLET in 1 BOTTLE (10135-735-60) PYRAZINAMIDE MARLEX PHARMACEUTICALS, INC 2022-03-01
10135-0735-90 90 TABLET in 1 BOTTLE (10135-735-90) PYRAZINAMIDE MARLEX PHARMACEUTICALS, INC 2022-03-01
33342-0447-03 10 TABLET in 1 BOTTLE (33342-447-03) Pyrazinamide Macleods Pharmaceuticals Limited 2020-07-27
33342-0447-07 30 TABLET in 1 BOTTLE (33342-447-07) Pyrazinamide Macleods Pharmaceuticals Limited 2020-07-27
33342-0447-09 60 TABLET in 1 BOTTLE (33342-447-09) Pyrazinamide Macleods Pharmaceuticals Limited 2020-07-27
33342-0447-10 90 TABLET in 1 BOTTLE (33342-447-10) Pyrazinamide Macleods Pharmaceuticals Limited 2020-07-27
33342-0447-11 100 TABLET in 1 BOTTLE (33342-447-11) Pyrazinamide Macleods Pharmaceuticals Limited 2020-07-27
33342-0447-12 10 TABLET in 1 BLISTER PACK (33342-447-12) Pyrazinamide Macleods Pharmaceuticals Limited 2020-07-27
33342-0447-15 500 TABLET in 1 BOTTLE (33342-447-15) Pyrazinamide Macleods Pharmaceuticals Limited 2020-07-27
60687-0789-01 100 BLISTER PACK in 1 CARTON (60687-789-01) / 1 TABLET in 1... Pyrazinamide American Health Packaging 2024-02-20
70954-0484-10 60 TABLET in 1 BOTTLE (70954-484-10) Pyrazinamide ANI Pharmaceuticals, Inc. 2021-05-11
70954-0484-20 90 TABLET in 1 BOTTLE (70954-484-20) Pyrazinamide ANI Pharmaceuticals, Inc. 2021-05-11
70954-0484-30 100 TABLET in 1 BOTTLE (70954-484-30) Pyrazinamide ANI Pharmaceuticals, Inc. 2021-05-11
Observed labelers: Macleods Pharmaceuticals Limited (7) · Hikma Pharmaceuticals USA Inc (4) · ANI Pharmaceuticals, Inc. (3) · MARLEX PHARMACEUTICALS, INC (3) · American Health Packaging (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$1.4536
Range $1.4536–$1.4536 · middle 50% $1.4536–$1.4536 · 10 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.